Clinical Trial Update: Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating zanubrutinib with rituximab and chemotherapy for newly diagnosed primary central nervous system lymphoma in patients intoleran…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Ruijin Hospital | Conditions: PCNSL | Phase 2 | Status: UNKNOWN